{"id":37382,"date":"2023-01-06T12:16:10","date_gmt":"2023-01-06T04:16:10","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=37382"},"modified":"2023-11-13T10:30:25","modified_gmt":"2023-11-13T02:30:25","slug":"human-fgf-basicfgf2bfgf%e8%a9%a6%e5%8a%91%e7%9b%92-elikine-human-bfgf-elisa-kit%e8%b2%a8%e8%99%9fket6006","status":"publish","type":"post","link":"http:\/\/biopioneer.com.tw\/?p=37382","title":{"rendered":"Human FGF basic\/FGF2\/bFGF\u8a66\u5291\u76d2 | EliKine\u2122 Human bFGF ELISA Kit\u8ca8\u865fKTE6006"},"content":{"rendered":"

Human FGF basic\/FGF2\/bFGF\u8a66\u5291\u76d2 | EliKine\u2122 Human bFGF ELISA Kit\u8ca8\u865fKTE6006<\/a><\/span><\/strong><\/p>\n

15.6 pg\/mL-1000 pg\/mL, \u6700\u4f4e\u9748\u654f\u5ea68 pg\/mL<\/u><\/strong><\/span><\/p>\n

\u6210\u7e96\u7dad\u7d30\u80de\u751f\u9577\u56e0\u5b502(fibroblast growth factor 2)\uff0c\u4e5f\u7a31\u70ba\u9e7c\u6027\u6210\u7e96\u7dad\u7d30\u80de\u751f\u9577\u56e0\u5b50\uff08bFGF\uff09\u548cFGF-\u03b2\u3002FGF2 \u57fa\u56e0\u7de8\u78bc\u7684\u86cb\u767d\u8cea\u662f\u6210\u7e96\u7dad\u7d30\u80de\u751f\u9577\u56e0\u5b50 (fibroblast growth factor , FGF) \u5bb6\u65cf\u7684\u6210\u54e1\u3002 FGF \u5bb6\u65cf\u6210\u54e1(FGF family members)\u7d50\u5408\u809d\u7d20(heparin)\u4e26\u5177\u6709\u5ee3\u6cdb\u7684\u4fc3\u6709\u7d72\u5206\u88c2(possess broad mitogenic)\u548c\u8840\u7ba1\u751f\u6210\u6d3b\u6027(angiogenic activities)\u3002\u9019\u7a2e\u86cb\u767d\u8cea\u8207\u591a\u7a2e\u751f\u7269\u904e\u7a0b\u6709\u95dc\uff0c\u4f8b\u5982\u80a2\u9ad4(limb)\u548c\u795e\u7d93\u7cfb\u7d71\u767c\u80b2(nervous system development)\u3001\u50b7\u53e3\u7652\u5408(wound healing)\u548c\u816b\u7624\u751f\u9577(tumor growth)\u3002\u8a72\u57fa\u56e0\u7684 mRNA \u5305\u542b\u591a\u500b\u805a\u817a\u82f7\u9178\u5316\u4f4d\u9ede(multiple polyadenylation sites)\uff0c\u4e26\u4e14\u53ef\u4ee5\u5f9e\u975e AUG (CUG) \u548c AUG \u8d77\u59cb\u5bc6\u78bc\u5b50\u7ffb\u8b6f\u800c\u4f86\uff0c\u5f9e\u800c\u7522\u751f\u5177\u6709\u4e0d\u540c\u7279\u6027\u7684\u4e94\u7a2e\u4e0d\u540c\u4e9e\u578b\u3002 CUG \u555f\u52d5\u7684\u4e9e\u578b\u4f4d\u65bc\u7d30\u80de\u6838(nucleus)\u4e2d\u4e26\u8ca0\u8cac\u5167\u5206\u6ccc\u4f5c\u7528(intracrine effect)\uff0c\u800c AUG \u555f\u52d5\u7684\u5f62\u5f0f(AUG-initiated form)\u4e3b\u8981\u662f\u7d30\u80de\u6eb6\u8cea(cytosolic)\u7684\u4e26\u4e14\u8ca0\u8cac\u8a72 FGF \u7684\u65c1\u5206\u6ccc(paracrine)\u548c\u81ea\u5206\u6ccc\u4f5c\u7528(autocrine effects)\u3002<\/p>\n

\"\"<\/a><\/span>\u7522\u54c1<\/strong>\u63cf\u8ff0\uff1a <\/strong>bFGF ELISA\u8a66\u5291\u76d2(EliKine\u2122 Human bFGF ELISA Kit\u8ca8\u865f<\/strong>KTE6006)\u63a1\u7528\u5169\u9ede\u593e\u5fc3ELISA (Sandwich ELISA)\u5b9a\u91cf\u6a23\u54c1\u4e2d\u7684bFGF\u3002\u5c0dbFGF\u7279\u7570\u7684\u6297\u9ad4\u5df2\u9810\u5148\u5305\u88ab\u5728\u5fae\u5b54\u677f\u4e0a\u3002\u5c07\u6a19\u6e96\u54c1\u548c\u6a23\u54c1\u5438\u53d6\u5230\u5b54\u4e2d\uff0c\u4e26\u4e14\u5b58\u5728\u7684\u4efb\u4f55bFGF\u90fd\u88ab\u56fa\u5b9a\u7684\u6297\u9ad4\u7d50\u5408\u3002\u9664\u53bb\u6240\u6709\u672a\u7d50\u5408\u7684\u7269\u8cea\u5f8c\uff0c\u5c07HRP-\u7db4\u5408bFGF\u6aa2\u6e2c\u6297\u9ad4\u6dfb\u52a0\u5230\u5b54\u4e2d\u3002\u6d17\u6ecc\u4ee5\u9664\u53bb\u4efb\u4f55\u672a\u7d50\u5408\u7684HRP\u8a66\u5291\u5f8c\uff0c\u5c07\u8272\u539f\u6eb6\u6db2\u6dfb\u52a0\u5230\u5b54\u4e2d\uff0c\u4e26\u4e14\u6839\u64da\u5728\u521d\u59cb\u6b65\u9a5f\u4e2d\u7d50\u5408\u7684bFGF\u7684\u91cf\u6210\u6bd4\u4f8b\u5730\u986f\u8272\u3002\u505c\u6b62\u986f\u8272\u4e26\u6e2c\u91cf\u984f\u8272\u7684\u5f37\u5ea6\u3002\u5075\u6e2c\u7bc4\u570d: 15.6 pg\/mL-1000 pg\/mL, \u6700\u4f4e\u9748\u654f\u5ea68 pg\/mL\u3002<\/strong>\u53ef\u61c9\u7528\u65bc\u4ee5\u4e0b\u6a23\u54c1\u4f86\u6e90: Cell culture supernatants, Other biological fluids, Plasma, Serum\u3002<\/p>\n

\"\"<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Product name<\/strong><\/td>\nEliKine\u2122 Human bFGF ELISA Kit<\/td>\n<\/tr>\n
Reactivity<\/strong><\/td>\nHuman<\/td>\n<\/tr>\n
Applications<\/strong><\/td>\nELISA<\/td>\n<\/tr>\n
Applications notes<\/strong><\/td>\nEliKine\u2122 Human bFGF ELISA Kit employs a two-site sandwich ELISA to quantitate bFGF in samples. An antibody specific for bFGF has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any bFGF present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for bFGF is added to the wells. After washing, proprietary EliKine\u2122 Streptavidin-HRP conjugates is added to the wells. Following a wash to remove any unbound streptavidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of bFGF bound in the initial step. The color development is stopped and the intensity of the color is measured.<\/td>\n<\/tr>\n
Detection method<\/strong><\/td>\nColorimetric<\/td>\n<\/tr>\n
SampleType<\/strong><\/td>\nCell culture supernatants, Other biological fluids, Plasma, Serum<\/td>\n<\/tr>\n
Assay type<\/strong><\/td>\nSandwich ELISA (quantitative)<\/td>\n<\/tr>\n
Assay duration<\/strong><\/td>\nMultiple steps standard sandwich ELISA assay with a working time of 3-5 hours. It depends on the experience of the operation person.<\/td>\n<\/tr>\n
Alternative<\/strong><\/td>\nBasic fibroblast growth factor; BFGF; FGF 2; FGF B; FGF2; FGF2 basic; FGFB; Fibroblast growth factor 2 (basic); HBGF 2; HBGF2; HBGH 2; Heparin binding growth; factor 2; Heparin binding growth factor 2 precursor; OTTMUSP00000046776; Prostatropin<\/td>\n<\/tr>\n
Kit components<\/strong><\/td>\n\u2022 Human bFGF microplate
\n\u2022 Human bFGF standard
\n\u2022 Human bFGF detect antibody
\n\u2022 Avidin-HRP
\n\u2022 Standard diluent
\n\u2022 Assay buffer
\n\u2022 HRP substrate
\n\u2022 Stop solution
\n\u2022 Wash buffer
\n\u2022 Plate covers.<\/td>\n<\/tr>\n
Features & Benefits<\/strong><\/td>\nEliKine\u2122 Human bFGF ELISA Kit has high sensitivity and excellent specificity for detection of Human bFGF. No significant cross-reactivity or interference between Human bFGF and analogues was observed.<\/td>\n<\/tr>\n
Calibration range<\/strong><\/td>\n15.6 pg\/mL-1000 pg\/mL<\/td>\n<\/tr>\n
Limit of detection<\/strong><\/td>\n8 pg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u7d30\u80de\u56e0\u5b50(Cytokine)\u529f\u80fd<\/strong><\/p>\n

\u7d30\u80de\u56e0\u5b50(Cytokine)\u5177\u6709\u591a\u7a2e\u751f\u7269\u5b78\u529f\u80fd\u3002\u5b83\u662f\u6025\u6027\u671f\u53cd\u61c9(acute phase response)\u7684\u6709\u6548\u8a98\u5c0e\u5291\u3002\u5728B\u7d30\u80de(B-cells)\u6700\u7d42\u5206\u5316\u70baIg\u5206\u6ccc\u7d30\u80de(Ig-secreting cells)\u7684\u6700\u7d42\u5206\u5316\u4e2d\u8d77\u91cd\u8981\u4f5c\u7528\uff0c\u53c3\u8207\u6dcb\u5df4\u7d30\u80de(lymphocyte)\u548c\u55ae\u6838\u7d30\u80de(monocyte)\u7684\u5206\u5316\u3002\u5b83\u8a98\u5c0e\u9aa8\u9ad3\u7624(myeloma)\u548c\u6f3f\u7d30\u80de\u7624(plasmacytoma growth)\u751f\u9577\uff0c\u4e26\u8a98\u5c0e\u795e\u7d93\u7d30\u80de\u5206\u5316(differentiation)\u3002\u4f5c\u7528\u65bcB\u7d30\u80de(B-cells)\uff0cT\u7d30\u80de(T-cells)\uff0c\u809d\u7d30\u80de(hepatocytes)\uff0c\u9020\u8840\u7956\u7d30\u80de(hematopoeitic progenitor cells)\u548cCNS\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u7d30\u80de\u3002\u4e5f\u53ef\u4ee5\u4f5c\u70ba\u808c\u8089\u56e0\u5b50(myokine)\u3002\u5b83\u5728\u808c\u8089\u6536\u7e2e\u5f8c\u6392\u5165\u8840\u6db2\uff0c\u4e26\u8d77\u5230\u589e\u52a0\u8102\u80aa\u5206\u89e3\u548c\u6539\u5584\u80f0\u5cf6\u7d20\u62b5\u6297(insulin resistance)\u7684\u4f5c\u7528\u3002<\/p>\n

\u708e\u6027\u7d30\u80de\u56e0\u5b50<\/strong><\/span><\/p>\n

\u708e\u75c7\u7531\u591a\u7a2e\u53ef\u6eb6\u6027\u56e0\u5b50\u4ecb\u5c0e\uff0c\u5305\u62ec\u4e00\u7d44\u7a31\u70ba\u7d30\u80de\u56e0\u5b50\u7684\u5206\u6ccc\u591a\u80bd\u3002\u708e\u6027\u7d30\u80de\u56e0\u5b50\u53ef\u5206\u70ba\u5169\u985e\uff1a\u53c3\u8207\u6025\u6027\u708e\u75c7\u7684\u7d30\u80de\u56e0\u5b50\u548c\u8ca0\u8cac\u4efb\u7684\u7d30\u80de\u56e0\u5b50\u3002\u708e\u75c7\u662f\u7d44\u7e54\u5c0d\u640d\u50b7\u7684\u53cd\u61c9\uff0c\u5176\u7279\u5fb5\u662f\u5728\u6025\u6027\u671f\u4ee5\u589e\u52a0\u7684\u8840\u6d41\u91cf\u548c\u8840\u7ba1\u901a\u900f\u6027\u4ee5\u53ca\u9ad4\u6db2\uff0c\u767d\u7d30\u80de\u548c\u708e\u6027\u4ecb\u8cea\uff08\u4f8b\u5982\u7d30\u80de\u56e0\u5b50\uff09\u7684\u7a4d\u7d2f\u70ba\u7279\u5fb5\u3002\u5e7e\u7a2e\u7d30\u80de\u56e0\u5b50\u5728\u4ecb\u5c0e\u6025\u6027\u708e\u75c7\u53cd\u61c9\u4e2d\u8d77\u95dc\u9375\u4f5c\u7528\uff0c\u5373IL-1\uff0cTNF-\u03b1\uff0cIL-6\uff0cIL-11\uff0cIL-8\u548c\u5176\u4ed6\u8da8\u5316\u56e0\u5b50\uff0cG-CSF\u548cGM-CSF\u3002<\/p>\n

\u5df2\u77e5\u53ef\u4ecb\u5c0e\u6162\u6027\u708e\u75c7\u904e\u7a0b\u7684\u7d30\u80de\u56e0\u5b50\u53ef\u5206\u70ba\u53c3\u8207\u9ad4\u6db2\u708e\u75c7\u7684\u7d30\u80de\u56e0\u5b50\uff0c\u4f8b\u5982IL-3\uff0cIL-4\uff0cIL-5\uff0cIL-6\uff0cIL-7\uff0cIL-9\uff0cIL-10\uff0cIL- 13\uff0c\u8f49\u5316\u751f\u9577\u56e0\u5b50b\uff08TGF-b\uff09\uff0c\u4ee5\u53ca\u90a3\u4e9b\u6709\u52a9\u65bc\u7d30\u80de\u708e\u75c7\u7684\u56e0\u5b50\uff0c\u4f8b\u5982IL-1\uff0cIL-2\uff0cIL-3\uff0cIL-4\uff0cIL-7\uff0cIL-9\uff0cIL-10\uff0c IL-12\uff0c\u5e72\u64fe\u7d20\uff08IFN\uff09\uff0cIFN-g\u8a98\u5c0e\u56e0\u5b50\uff08IGIF\uff09\uff0cTGF-b\u548cTNF-a\u548c-b\u3002\u708e\u75c7\u7570\u5e38\u662f\u4e00\u5927\u985e\u75be\u75c5\uff0c\u662f\u8a31\u591a\u4eba\u985e\u75be\u75c5\u7684\u57fa\u790e\u3002\u7d30\u80de\u56e0\u5b50\u662f\u5bbf\u4e3b\u5c0d\u611f\u67d3\uff0c\u514d\u75ab\u53cd\u61c9\uff0c\u708e\u75c7\u548c\u5275\u50b7\u53cd\u61c9\u7684\u8abf\u7bc0\u5291\u3002\u4e00\u4e9b\u7d30\u80de\u56e0\u5b50\u8d77\u4f7f\u75be\u75c5\u60e1\u5316\u7684\u4f5c\u7528\uff08\u4fc3\u708e\u7d30\u80de\u56e0\u5b50\uff09\uff0c\u800c\u53e6\u4e00\u4e9b\u7d30\u80de\u56e0\u5b50\u8d77\u6e1b\u8f15\u708e\u75c7\u548c\u4fc3\u9032\u7652\u5408\u7684\u4f5c\u7528\uff08\u6297\u708e\u7d30\u80de\u56e0\u5b50\uff09\u3002<\/p>\n

\u767d\u4ecb\u7d20-1\uff08Interleukin-1, IL-1\uff09\u662f\u6709\u53f2\u4ee5\u4f86\u6700\u65e9\u7684\u7d30\u80de\u56e0\u5b50(cytokines)\u4e4b\u4e00\u3002\u5b83\u7684\u6700\u521d\u767c\u73fe\u662f\u53ef\u80fd\u8a98\u767c\u767c\u71d2(fever)\uff0c\u63a7\u5236\u6dcb\u5df4\u7d30\u80de(lymphocytes)\uff0c\u589e\u52a0\u9aa8\u9ad3\u7d30\u80de\u6578\u91cf(bone marrow cells)\u4e26\u5f15\u8d77\u9aa8\u95dc\u7bc0\u9000\u5316\u7684\u56e0\u7d20\u3002\u6b64\u6642\uff0cIL-1\u4ee5\u5176\u4ed6\u5e7e\u7a2e\u540d\u7a31\u70ba\u4eba\u6240\u77e5\uff0c\u5305\u62ec\u5167\u6e90\u6027\u71b1\u539f(endogenous pyrogen)\uff0c\u6dcb\u5df4\u7d30\u80de\u6d3b\u5316\u56e0\u5b50(lymphocyte activating factor)\uff0c\u9020\u8840\u7d20-1(haemopoetin-1)\u548c\u55ae\u6838\u7d30\u80de\u56e0\u5b50(mononuclear cell factor)\u7b49\u3002\u5927\u7d04\u57281984\u5e74\u81f31985\u5e74\u9593\uff0c\u79d1\u5b78\u5bb6\u5011\u8b49\u5be6IL-1\u5be6\u969b\u4e0a\u7531\u5169\u7a2e\u4e0d\u540c\u7684\u86cb\u767d\u8cea\u7d44\u6210\uff0c\u73fe\u5728\u7a31\u70baIL-1\u03b1\u548cIL-1\u03b2\uff0c\u5b83\u5011\u5c6c\u65bc\u7a31\u70ba\u767d\u7d30\u80de\u4ecb\u7d201\u8d85\u5bb6\u65cf\u7684\u7d30\u80de\u56e0\u5b50\u5bb6\u65cf\u3002 IL-1\u03b2\u7531\u5de8\u566c\u7d30\u80de(macrophages)\uff0c\u55ae\u6838\u7d30\u80de(monocytes)\u548c\u6a39\u7a81\u72c0\u7d30\u80de(dendritic cells)\u7522\u751f\u3002<\/p>\n

IFN-\u03b3\uff08IFN-gamma, \u5e72\u64fe\u7d20-\u03b3\uff09\u662f\u4fc3\u708e(proinflammatory)\u7d30\u80de\u56e0\u5b50(cytokine)\u7684\u539f\u578b(prototype)\uff0c\u7531\u591a\u7a2e\u514d\u75ab\u7d30\u80de(immune cells)\u5728\u708e\u6027(inflammatory)\u689d\u4ef6\u4e0b\u7522\u751f\uff0c\u7279\u5225\u662f\u7531T\u7d30\u80de(T cells)\u548cNK\u7d30\u80de(NK cells)\u7522\u751f\u3002\u5b83\u901a\u904e\u4fc3\u9032Th1\u7d30\u80de\u7684\u767c\u80b2(development)\u548c\u6fc0\u6d3b(activation)\uff0c\u55ae\u6838\u7d30\u80de(monocytes)\u548c\u5de8\u566c\u7d30\u80de(macrophage)\u7684\u5316\u5b78\u5f15\u8a98(chemoattraction)\u548c\u6fc0\u6d3b(activation)\uff0c\u6297\u539f\u5448\u905e\u5206\u5b50(antigen presentation molecules)\u7684\u4e0a\u8abf\u4ee5\u53caB\u7d30\u80de\u4e2d\u7684\u514d\u75ab\u7403\u86cb\u767d\u985e\u5225\u8f49\u63db(immunoglobulin class switching)\uff0c\u5728\u5bbf\u4e3b\u9632\u79a6\u4e2d\u8d77\u95dc\u9375\u4f5c\u7528\u3002\u5b83\u9084\u5177\u6709\u6297\u75c5\u6bd2(antiviral)\uff0c\u6297\u589e\u6b96(antiproliferative)\u548c\u51cb\u4ea1\u4f5c\u7528(apoptotic)\u3002\u53e6\u5916\uff0cIFN-\u03b3\u901a\u904e\u4fc3\u9032\u8abf\u7bc0\u6027T\u7d30\u80de\u7684\u767c\u80b2\u4e26\u6291\u5236Th17\u7d30\u80de\u5206\u5316\u800c\u5145\u7576\u6297\u708e\u4ecb\u8cea\u3002 IFN-\u03b3\u4e8c\u805a\u9ad4\u901a\u904e\u5169\u500bIFN-\u03b3R1\u548c\u5169\u500bIFN-\u03b3R2\u4e9e\u57fa\u7684\u53d7\u9ad4\u8907\u5408\u7269\u767c\u51fa\u4fe1\u865f\u3002<\/p>\n

\u767d\u7d30\u80de\u4ecb\u7d2017 (Interleukin 17, IL17)<\/p>\n

IL-17\u57fa\u56e0\u7de8\u78bc( IL-17 gene)\u7684\u86cb\u767d\u8cea\u662f\u7531\u6d3b\u5316\u7684T\u7d30\u80de(activated T cells)\u6240\u7522\u751f\u7684\u4fc3\u767c\u708e\u7d30\u80de\u6fc0\u7d20\u3002\u6b64\u7d30\u80de\u6fc0\u7d20\u8abf\u7bc0 NF-\u03baB \u548c\u7d72\u88c2\u539f\u6d3b\u5316\u86cb\u767d\u6fc0\u9176(mitogen-activated protein kinases)\u7684\u6d3b\u6027\u3002\u9019\u7a2e\u7d30\u80de\u6fc0\u7d20(cytokine )\u53ef\u4ee5\u523a\u6fc0 IL6 \u548c\u74b0\u6c27\u5408\u9176-2 (cyclooxygenase-2, PTGS2\/COX-2) \u7684\u8868\u9054\uff0c\u4e26\u589e\u5f37\u4e00\u6c27\u5316\u6c2e (nitric oxide, NO) \u7684\u7522\u751f\u3002\u9ad8\u6c34\u5e73\u7684\u9019\u7a2e\u7d30\u80de\u6fc0\u7d20\u8207\u591a\u7a2e\u6162\u6027\u767c\u708e\u6027\u75be\u75c5\u6709\u95dc\uff0c\u5305\u62ec\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(rheumatoid arthritis)\u3001\u725b\u76ae\u766c(psoriasis )\u548c\u591a\u767c\u6027\u786c\u5316\u75c7(multiple sclerosis)\u3002<\/p>\n

\u767d\u8840\u7403\u4ecb\u7d20-8\uff08Interleukin-8, IL8)<\/p>\n

IL-8\u57fa\u56e0\u7de8\u78bc(IL-8 gene)\u7684\u86cb\u767d\u8cea\u662fCXC\u8da8\u5316\u56e0\u5b50\u5bb6\u65cf(CXC chemokine family)\u7684\u6210\u54e1\u3002\u9019\u7a2e\u8da8\u5316\u56e0\u5b50(chemokine )\u662f\u767c\u708e\u53cd\u61c9(inflammatory response)\u7684\u4e3b\u8981\u4ecb\u8cea\u4e4b\u4e00\u3002\u9019\u7a2e\u8da8\u5316\u56e0\u5b50\u7531\u591a\u7a2e\u7d30\u80de\u985e\u578b\u5206\u6ccc\u3002\u5b83\u5177\u6709\u5316\u5b78\u5f15\u8a98\u5291( chemoattractant)\u7684\u4f5c\u7528\uff0c\u4e5f\u662f\u4e00\u7a2e\u6709\u6548\u7684\u8840\u7ba1\u751f\u6210\u56e0\u5b50(angiogenic factor)\u3002 IL-8\u57fa\u56e0\u88ab\u8a8d\u70ba\u5728\u7d30\u652f\u6c23\u7ba1\u708e\uff08\u4e00\u7a2e\u7531\u75c5\u6bd2\u611f\u67d3\u5f15\u8d77\u7684\u5e38\u898b\u547c\u5438\u9053\u75be\u75c5\uff09\u7684\u767c\u75c5\u6a5f\u5236(pathogenesis )\u4e2d\u767c\u63ee\u4f5c\u7528\u3002 IL-8\u57fa\u56e0(IL-8 gene )\u548cCXC\u8da8\u5316\u56e0\u5b50\u57fa\u56e0\u5bb6\u65cf(CXC chemokine gene family)\u7684\u5176\u4ed610\u500b\u6210\u54e1\u5728\u5b9a\u4f4d\u65bc\u67d3\u8272\u9ad44q( chromosome 4q)\u7684\u5340\u57df\u4e2d\u5f62\u6210\u8da8\u5316\u56e0\u5b50\u57fa\u56e0\u7c07(chemokine gene cluster )\u3002<\/p>\n

\u4f7f\u7528\u6ce8\u610f\u4e8b\u9805<\/span><\/strong><\/p>\n